Serum Biomarkers in Neuro-Ophthalmology: When to Test

ABSTRACT

Discovery and characterization of serologic biomarkers has revolutionized the diagnostic framework of systemic and paraneoplastic autoimmune neuro-ophthalmic diseases. Expanding recognition of the multiple ocular and visual manifestations of these conditions highlights the important role of the referring provider in identifying potential cases. Increasing ease of access to serologic testing also enables these practitioners to initiate the diagnostic work-up in suspected cases. We aimed to provide an update on the current knowledge surrounding and use of relevant autoimmune biomarkers by correlating specific clinical neuro-ophthalmic manifestations with autoantibody biomarkers. The utility of select biomarkers for myasthenia gravis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein-IgG-associated disorder, opsoclonus–myoclonus syndrome, anti-collapsin-response mediator protein-5 optic neuropathy, and glial fibrillary acidic protein-IgG-associated disease are discussed with particular focus on the clinical contexts in which to consider testing.

KEYWORDS:

• Autoantibodies
• autoimmune neuro-ophthalmic disorders
• neuro-ophthalmology
• paraneoplastic syndromes
• serum biomarkers

Disclosure Statement

EDG: Luminopia, Inc. (equity; patent; advisor); Stoke Therapeutics, Inc. (consultant).